Free US stock valuation models and price target projections from professional analysts covering Wall Street expectations and analyst consensus. We help you understand fair value estimates and potential upside or downside scenarios for any stock you are considering. Our platform provides multiple valuation methods, comparable company analysis, and discounted cash flow models. Make smarter valuation decisions with our comprehensive tools and expert projections based on Wall Street research.
ProKidney Corp. (PROK), a clinical-stage biotech firm focused on developing cell-based therapies for chronic kidney disease, is trading at $2.12 as of 2026-04-20, representing a 2.75% decline on the day. This analysis outlines key technical levels, prevailing market context, and potential near-term scenarios for the stock, with no company-specific headlines driving the day’s price action per available market data. No recent earnings data is available for ProKidney Corp. as of this analysis, so r
ProKidney (PROK) Stock Live Trade (On the Radar) 2026-04-20 - Analyst Recommended Stocks
PROK - Stock Analysis
4137 Comments
671 Likes
1
Jkari
Regular Reader
2 hours ago
I understood enough to worry.
👍 211
Reply
2
Noralba
Legendary User
5 hours ago
I read this and now I need water.
👍 28
Reply
3
Aladrian
Registered User
1 day ago
Investors are balancing potential gains with risk considerations, focusing on disciplined allocation strategies.
👍 214
Reply
4
Makyia
Engaged Reader
1 day ago
Wish I’d read this yesterday. 😔
👍 96
Reply
5
Addrienne
Registered User
2 days ago
I read this and now I’m thinking differently.
👍 46
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.